Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience

被引:28
作者
Bar-Ad, Voichita [1 ]
Zhang, Qiang [2 ]
Harari, Paul M. [3 ]
Axelrod, Rita [1 ]
Rosenthal, David I. [4 ]
Trotti, Andy [5 ]
Jones, Christopher U. [6 ]
Garden, Adam S. [4 ]
Song, Guobin [7 ]
Foote, Robert L. [8 ]
Raben, David [9 ]
Shenouda, George [10 ]
Spencer, Sharon A. [11 ]
Harris, Jonathan [2 ]
Quynh-Thu Le [12 ]
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA
[2] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA
[3] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Radiol Associates Sacramento, Sacramento, CA USA
[7] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[8] Mayo Clin, Rochester, MN USA
[9] Univ Colorado, Ctr Comprehens Canc, Denver, CO 80202 USA
[10] McGill Univ, Montreal, PQ, Canada
[11] Univ Alabama Birmingham, Birmingham, AL USA
[12] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2016年 / 95卷 / 05期
关键词
METASTATIC COLORECTAL-CANCER; SQUAMOUS-CELL CARCINOMA; ACUTE ORGAN TOXICITY; POSITIVE PROGNOSTIC-FACTOR; MULTICENTER PHASE-II; LUNG-CANCER; RECEIVING CETUXIMAB; SINGLE-AGENT; CHEMOTHERAPY; COMBINATION;
D O I
10.1016/j.ijrobp.2016.03.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the severity of cetuximab-induced skin rash and its correlation with clinical outcome and late skin toxicity in patients with head and neck squamous cell carcinoma treated with chemoradiation therapy and cetuximab. Methods and Materials: Analysis included patients who received loading dose and >= 1 cetuximab dose concurrent with definitive chemoradiation therapy (70 Gy + cisplatin) or postoperative chemoradiation therapy (60-66 Gy + docetaxel or cisplatin). Results: Six hundred two patients were analyzed; 383 (63.6%) developed grade 2 to 4 cetuximab rash. Patients manifesting grade 2 to 4 rash had younger age (P<.001), fewer pack-years smoking history (P<.001), were more likely to be males (P=.04), and had p16-negative (P=.04) oropharyngeal tumors (P=.003). In univariate analysis, grade 2 to 4 rash was associated with better overall survival (hazard ratio [HR] 0.58, P<.001) and progression-free survival (HR 0.75, P=.02), and reduced distant metastasis rate (HR 0.61, P=.03), but not local-regional failure (HR 0.79, P=.16) relative to grade 0 to 1 rash. In multivariable analysis, HRs for overall survival, progression-free survival, distant metastasis, and local-regional failure were, respectively, 0.68 (P=.008), 0.85 (P=.21), 0.64 (P=.06), and 0.89 (P=.48). Grade >= 2 rash was associated with improved survival in p16-negative patients (HR 0.28 [95% confidence interval 0.11-0.74]) but not in p16-positive patients (HR 1.10 [0.42-2.89]) (P=.05 for interaction). Twenty-five percent of patients with grade 2 to 4 acute in-field radiation dermatitis experienced grade 2 to 4 late skin fibrosis, versus 14% of patients with grade 0 to 1 acute in-field radiation dermatitis (P=.002). Conclusion: Grade 2 to 4 cetuximab rash was associated with better survival, possibly due to reduction of distant metastasis. This observation was noted mainly in p16-negative patients. Grade 2 to 4 acute in-field radiation dermatitis was associated with higher rate of late grade 2 to 4 skin fibrosis. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:1346 / 1354
页数:9
相关论文
共 35 条
[1]   Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522 [J].
Ang, K. Kian ;
Zhang, Qiang ;
Rosenthal, David I. ;
Nguyen-Tan, Phuc Felix ;
Sherman, Eric J. ;
Weber, Randal S. ;
Galvin, James M. ;
Bonner, James A. ;
Harris, Jonathan ;
El-Naggar, Adel K. ;
Gillison, Maura L. ;
Jordan, Richard C. ;
Konski, Andre A. ;
Thorstad, Wade L. ;
Trotti, Andy ;
Beitler, Jonathan J. ;
Garden, Adam S. ;
Spanos, William J. ;
Yom, Sue S. ;
Axelrod, Rita S. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2940-+
[2]  
Ang KK, 2002, CANCER RES, V62, P7350
[3]   Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer:: a phase Ib/II study of the AIO GI Group [J].
Arnold, D. ;
Hoehler, T. ;
Dittrich, C. ;
Lordick, F. ;
Seufferlein, T. ;
Riemann, J. ;
Woell, E. ;
Herrmann, T. ;
Zubel, A. ;
Schmoll, H. -J. .
ANNALS OF ONCOLOGY, 2008, 19 (08) :1442-1449
[4]   The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis [J].
Balagula, Y. ;
Wu, S. ;
Su, X. ;
Lacouture, M. E. .
ANNALS OF ONCOLOGY, 2011, 22 (11) :2366-2374
[5]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[6]  
Bonner JA, 2000, J CLIN ONCOL, V18, p47S
[7]   Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J].
Bonner, James A. ;
Harari, Paul M. ;
Giralt, Jordi ;
Cohen, Roger B. ;
Jones, Christopher U. ;
Sur, Ranjan K. ;
Raben, David ;
Baselga, Jose ;
Spencer, Sharon A. ;
Zhu, Junming ;
Youssoufian, Hagop ;
Rowinsky, Eric K. ;
Ang, K. Kian .
LANCET ONCOLOGY, 2010, 11 (01) :21-28
[8]   Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 gortec phase II trial [J].
Calais, G ;
Bardet, E ;
Sire, C ;
Alfonsi, M ;
Bourhis, J ;
Rhein, B ;
Tortochaux, J ;
Man, YTK ;
Auvray, H ;
Garaud, P .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (01) :161-166
[9]   How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? [J].
Chan, Alexandre ;
Tan, Eng Hooi .
SUPPORTIVE CARE IN CANCER, 2011, 19 (10) :1667-1674
[10]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345